TheraRadar
Clinical-Stage Companies / Shanghai Mabgeek Biotech.

Shanghai Mabgeek Biotech.

Pre-Approval PRO BETA
9
Total Trials
6
Phase 3
4
Phase 2
5
Recruiting
150
Score

Pipeline by Phase

Phase 3
6
Phase 2
4
Phase 1
1

Therapeutic Focus

Atopic Dermatitis Atopic Eczema Atopic Dermatitis (AD) Bronchial Asthma Prurigo Nodularis

Clinical Trials (9)

NCT06779136 Phase 3 RECRUITING

Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis

Started: 2/26/2025

NCT06837922 Phase 3 RECRUITING

Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma

Started: 3/25/2025

NCT07479615 Phase 3 NOT YET RECRUITING

A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic Dermatitis

Started: 5/1/2026

NCT07546487 Phase 3 NOT YET RECRUITING

A Study of MG-K10 in Chronic Spontaneous Urticaria

Started: 4/14/2026

NCT07540442 Phase 3 NOT YET RECRUITING

A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis

Started: 4/17/2026

NCT06846385 Phase 2 RECRUITING

Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic Rhinitis

Started: 3/20/2025

NCT07103174 Phase 2 NOT YET RECRUITING

A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis

Started: 8/16/2025

NCT07054034 Phase 2 ACTIVE NOT RECRUITING

Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects

Started: 5/11/2025

NCT06765005 Phase 1 RECRUITING

IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients

Started: 7/19/2024

Drug Candidates

MG-K10 Humanized Monoclonal Antibody Injection MG-K10 placebo MG-ZG122 Humanized Monoclonal Antibody Injection Placebo MG-K10/Placebo MG-K10 MG-K10 Injection (Humanized Monoclonal Antibody) Placebo for MG-K10
Activity Status: Active
Last Trial Started: 5/1/2026
Last Trial Ended: N/A
Trials (12 months): 5
Completed Trials: 0
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.